三博脑科(301293) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥354,942,315.27, representing a 9.67% increase compared to ¥320,537,369.42 in the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥37,925,023.10, a 28.13% increase from ¥28,656,848.84 in the previous year[2] - The net profit after deducting non-recurring gains and losses decreased by 21.78% to ¥24,269,317.09 from ¥30,085,691.37 in the same period last year[2] - The basic earnings per share for Q3 2024 was ¥0.18, up 28.57% from ¥0.14 in the previous year[2] - The weighted average return on net assets for Q3 2024 was 1.62%, an increase from 1.24% in the same period last year[2] - The net profit for Q3 2024 reached CNY 116,938,114.94, a 41.6% increase compared to CNY 82,562,267.02 in the same period last year[16] - Operating profit for the quarter was CNY 139,920,460.91, up from CNY 115,196,314.32, reflecting a growth of 21.5% year-over-year[16] - The total profit for the quarter was CNY 149,190,034.41, compared to CNY 108,261,817.93 in the same quarter last year, marking an increase of 37.9%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,134,086,644.39, a decrease of 4.01% compared to the previous year's end[2] - As of September 30, 2024, the company's total assets amounted to 3,008,270,390.01 yuan, a decrease from 3,134,086,644.39 yuan at the beginning of the period[14] - The company's total current assets decreased to 1,446,528,709.45 yuan from 1,733,613,039.97 yuan at the beginning of the period, reflecting a decline of approximately 16.6%[13] - The company's accounts payable decreased significantly to 185,515,688.98 yuan from 252,581,968.11 yuan, a reduction of approximately 26.5%[14] - The company's non-current liabilities decreased to 150,558,295.48 yuan from 183,521,421.43 yuan, a decline of about 18%[14] - The company's retained earnings increased to 554,849,627.05 yuan from 465,349,923.34 yuan, reflecting an increase of approximately 19.2%[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥131,826,178.80, down 24.04% from ¥170,894,245.87 in the same period last year[2] - Cash flow from operating activities generated a net amount of CNY 131,826,178.80, down from CNY 173,546,003.10 in the same quarter last year[20] - The company's cash and cash equivalents decreased to 755,145,195.14 yuan from 822,122,353.04 yuan, a decline of about 8.2%[12] - The company reported cash and cash equivalents at the end of the period totaling CNY 748,745,195.14, down from CNY 960,586,300.62 at the end of Q3 2023[20] - Investment activities resulted in a net cash outflow of CNY 51,483,310.76, an improvement from a net outflow of CNY 845,276,929.17 in Q3 2023[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,403, with the largest shareholder, TBP 3Doctors (HK) Limited, holding 15.70% of shares, equating to 32,330,025 shares[8] - Zhang Yang, a significant shareholder, holds 10.59% of shares, totaling 21,815,703 shares, with 21,815,703 shares subject to lock-up[9] - The company repurchased 2,997,183 common shares, representing 1.86% of the total share capital[9] - The total number of restricted shares at the beginning of the period was 122,453,493, with 87,806,343 shares released during the period, resulting in 45,041,295 restricted shares remaining[10] - The company plans to release 24,869,250 shares held by TBP 3Doctors (HK) Limited on May 10, 2024, as part of the initial public offering lock-up[9] - The number of shares held by Lin Ruiyan, another major shareholder, is 4,953,818, all of which are unrestricted[8] - The company has a total of 33,685,118 restricted shares that will be released on May 10, 2024, as part of the initial public offering[10] - The total number of shares held by the top ten unrestricted shareholders is 56,000,000, with TBP 3Doctors (HK) Limited being the largest[8] - The company has seen an increase in the number of shares held by Zhang Yang and Luan Guoming due to the release of restricted shares[9] - The company has no reported changes in the relationships among shareholders or any actions as a concerted group[9] Government and Project Funding - The company reported a government subsidy of ¥880,755.47 for the current period, primarily related to project funding[4] - The acquisition of Chongqing Xida Pharmaceutical Co., Ltd. contributed positively to the net profit for the year-to-date period[6] - The company experienced a decrease in net profit attributable to shareholders after deducting non-recurring gains and losses due to expenses related to a research project with Tsinghua University[6] - The company plans to use a total of 420 million yuan from its own funds and raised funds to increase capital in its wholly-owned subsidiary, Chongqing Sanbo Property Management Co., Ltd., and to acquire 70% equity in Sichuan Dahang Guangze Medical Investment Management Co., Ltd.[11] Research and Development - The company reported a significant increase in research and development expenses, although specific figures were not disclosed[15] Accounting and Reporting - The third quarter report of Sanbo Brain Hospital Management Group Co., Ltd. is unaudited[21] - The company will implement new accounting standards starting in 2024[21] - The report was released on October 25, 2024[21] - The financial statement adjustments related to the first-time implementation of new accounting standards are applicable[21] - The board of directors has approved the third quarter report[21] - There are no specific performance summaries or user data provided in the report[21] - Future outlook and performance guidance details are not included in the report[21] - No information on new product or technology development is mentioned[21] - Market expansion and acquisition strategies are not discussed in the report[21] - Other new strategies are not outlined in the report[21]